Estimation of renal cell carcinoma treatment effects from disease progression modeling

M. L. Maitland, K. Wu, M. R. Sharma, Y. Jin, S. P. Kang, W. M. Stadler, T. G. Karrison, M. J. Ratain, Robert Bies

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

To improve future drug development efficiency in renal cell carcinoma (RCC), a disease-progression model was developed with longitudinal tumor size data from a phase III trial of sorafenib in RCC. The best-fit model was externally evaluated on 145 placebo-treated patients in a phase III trial of pazopanib; the model incorporated baseline tumor size, a linear disease-progression component, and an exponential drug effect (DE) parameter. With the model-estimated effect of sorafenib on RCC growth, we calculated the power of randomized phase II trials between sorafenib and hypothetical comparators over a range of effects. A hypothetical comparator with 80% greater DE than sorafenib would have 82% power (one-sided α = 0.1) with 50 patients per arm. Model-based quantitation of treatment effect with computed tomography (CT) imaging offers a scaffold on which to develop new, more efficient, phase II trial end points and analytic strategies for RCC.

Original languageEnglish
Pages (from-to)345-351
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume93
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Renal Cell Carcinoma
Disease Progression
Pharmaceutical Preparations
Therapeutics
Neoplasms
Tomography
Placebos
sorafenib
Growth

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Estimation of renal cell carcinoma treatment effects from disease progression modeling. / Maitland, M. L.; Wu, K.; Sharma, M. R.; Jin, Y.; Kang, S. P.; Stadler, W. M.; Karrison, T. G.; Ratain, M. J.; Bies, Robert.

In: Clinical Pharmacology and Therapeutics, Vol. 93, No. 4, 04.2013, p. 345-351.

Research output: Contribution to journalArticle

Maitland, ML, Wu, K, Sharma, MR, Jin, Y, Kang, SP, Stadler, WM, Karrison, TG, Ratain, MJ & Bies, R 2013, 'Estimation of renal cell carcinoma treatment effects from disease progression modeling', Clinical Pharmacology and Therapeutics, vol. 93, no. 4, pp. 345-351. https://doi.org/10.1038/clpt.2012.263
Maitland, M. L. ; Wu, K. ; Sharma, M. R. ; Jin, Y. ; Kang, S. P. ; Stadler, W. M. ; Karrison, T. G. ; Ratain, M. J. ; Bies, Robert. / Estimation of renal cell carcinoma treatment effects from disease progression modeling. In: Clinical Pharmacology and Therapeutics. 2013 ; Vol. 93, No. 4. pp. 345-351.
@article{5ad70b77ae3044aa847e05740932ec4f,
title = "Estimation of renal cell carcinoma treatment effects from disease progression modeling",
abstract = "To improve future drug development efficiency in renal cell carcinoma (RCC), a disease-progression model was developed with longitudinal tumor size data from a phase III trial of sorafenib in RCC. The best-fit model was externally evaluated on 145 placebo-treated patients in a phase III trial of pazopanib; the model incorporated baseline tumor size, a linear disease-progression component, and an exponential drug effect (DE) parameter. With the model-estimated effect of sorafenib on RCC growth, we calculated the power of randomized phase II trials between sorafenib and hypothetical comparators over a range of effects. A hypothetical comparator with 80{\%} greater DE than sorafenib would have 82{\%} power (one-sided α = 0.1) with 50 patients per arm. Model-based quantitation of treatment effect with computed tomography (CT) imaging offers a scaffold on which to develop new, more efficient, phase II trial end points and analytic strategies for RCC.",
author = "Maitland, {M. L.} and K. Wu and Sharma, {M. R.} and Y. Jin and Kang, {S. P.} and Stadler, {W. M.} and Karrison, {T. G.} and Ratain, {M. J.} and Robert Bies",
year = "2013",
month = "4",
doi = "10.1038/clpt.2012.263",
language = "English",
volume = "93",
pages = "345--351",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Estimation of renal cell carcinoma treatment effects from disease progression modeling

AU - Maitland, M. L.

AU - Wu, K.

AU - Sharma, M. R.

AU - Jin, Y.

AU - Kang, S. P.

AU - Stadler, W. M.

AU - Karrison, T. G.

AU - Ratain, M. J.

AU - Bies, Robert

PY - 2013/4

Y1 - 2013/4

N2 - To improve future drug development efficiency in renal cell carcinoma (RCC), a disease-progression model was developed with longitudinal tumor size data from a phase III trial of sorafenib in RCC. The best-fit model was externally evaluated on 145 placebo-treated patients in a phase III trial of pazopanib; the model incorporated baseline tumor size, a linear disease-progression component, and an exponential drug effect (DE) parameter. With the model-estimated effect of sorafenib on RCC growth, we calculated the power of randomized phase II trials between sorafenib and hypothetical comparators over a range of effects. A hypothetical comparator with 80% greater DE than sorafenib would have 82% power (one-sided α = 0.1) with 50 patients per arm. Model-based quantitation of treatment effect with computed tomography (CT) imaging offers a scaffold on which to develop new, more efficient, phase II trial end points and analytic strategies for RCC.

AB - To improve future drug development efficiency in renal cell carcinoma (RCC), a disease-progression model was developed with longitudinal tumor size data from a phase III trial of sorafenib in RCC. The best-fit model was externally evaluated on 145 placebo-treated patients in a phase III trial of pazopanib; the model incorporated baseline tumor size, a linear disease-progression component, and an exponential drug effect (DE) parameter. With the model-estimated effect of sorafenib on RCC growth, we calculated the power of randomized phase II trials between sorafenib and hypothetical comparators over a range of effects. A hypothetical comparator with 80% greater DE than sorafenib would have 82% power (one-sided α = 0.1) with 50 patients per arm. Model-based quantitation of treatment effect with computed tomography (CT) imaging offers a scaffold on which to develop new, more efficient, phase II trial end points and analytic strategies for RCC.

UR - http://www.scopus.com/inward/record.url?scp=84875412326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875412326&partnerID=8YFLogxK

U2 - 10.1038/clpt.2012.263

DO - 10.1038/clpt.2012.263

M3 - Article

VL - 93

SP - 345

EP - 351

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -